Convalescent plasma is the liquid portion of blood collected from people who have recovered from an infection. It contains antibodies their immune system built to fight that specific pathogen. When transfused into a sick patient, those antibodies provide a borrowed defense, helping the recipient’s body fight the same infection without having to build its own immune response from scratch. This concept, called passive immunity, has been used in clinical settings for over 100 years.
How It Works in the Body
When you recover from a viral infection, your blood carries neutralizing antibodies that can recognize and disable that virus. Convalescent plasma delivers those antibodies directly into a new patient’s bloodstream. Once there, the antibodies work in two main ways: they latch onto the virus and block it from entering cells, and they flag infected cells so the patient’s own immune system can destroy them more efficiently. This clears the virus from the blood and can also help eliminate cells that are already harboring the infection.
The key difference between this and a vaccine is timing and effort. A vaccine trains your immune system to produce its own antibodies over days or weeks. Convalescent plasma skips that process entirely, giving you someone else’s antibodies right away. The trade-off is that the protection is temporary. Your body doesn’t “learn” from borrowed antibodies the way it would from a vaccine or natural infection, so the effect fades as those antibodies break down.
How Plasma Is Collected
Donors go through a process called apheresis, where blood is drawn, the plasma is separated out, and the red blood cells and other components are returned to the donor’s body. This avoids unnecessary red blood cell loss and maximizes the volume of usable plasma from each session. Modern apheresis equipment produces plasma that is filtered to remove white blood cells and is essentially cell-free, reducing the risk of contamination. A single session can sometimes yield enough plasma for one or two treatment doses, with each dose typically around 200 mL.
Not all plasma is equally useful. Donors need to have sufficiently high levels of antibodies against the target virus. During the COVID-19 pandemic, the FDA distinguished between “high titer” plasma (with strong antibody concentrations) and “low titer” plasma, requiring each unit to be tested and labeled accordingly. High-titer plasma proved significantly more effective at reducing mortality than low-titer plasma.
A Century of Use Before COVID-19
Convalescent plasma predates modern medicine by decades. Before antibiotics existed, it was widely used against both bacterial and viral diseases. A meta-analysis of its use during the 1918 influenza pandemic estimated it contributed to roughly a 20% absolute reduction in mortality. One of the most striking historical results came from a trial treating Argentine hemorrhagic fever: mortality was 1.1% among patients who received convalescent plasma compared to 16.5% in those who received normal plasma.
Over the past two decades, plasma has been explored against SARS, avian influenza, Ebola, and Lassa fever with varying results. A broad analysis of 32 studies across these infections found a 75% reduced risk of death overall, particularly when plasma was given early after symptoms appeared. In one documented case from 1976, a laboratory technician survived Ebola after receiving two plasma transfusions combined with other treatments. For avian flu (H5N1), a case report from southern China described a 31-year-old patient whose viral load kept climbing despite antiviral medication. After three 200 mL transfusions of convalescent plasma, his antibody levels rose steadily and he recovered.
The COVID-19 Experience
COVID-19 brought convalescent plasma into mainstream awareness. Early in the pandemic, with no vaccines or targeted treatments available, it became one of the few options for hospitalized patients. The FDA initially granted emergency use authorization, and large-scale studies followed. In a Mayo Clinic analysis of over 35,000 hospitalized patients, the seven-day mortality rate was lower in patients who received plasma within three days of diagnosis compared to those treated four or more days later. The same pattern held for 30-day mortality. Higher antibody levels in the donated plasma also correlated with better survival.
A Chinese trial of 103 patients with severe COVID-19 found that 87.2% of those who received convalescent plasma tested negative for the virus within 72 hours, compared to 37.5% in the standard care group. However, clinical improvement at 28 days was statistically significant only in patients with severe disease, not those who were already in life-threatening condition. This reinforced a consistent finding across diseases: convalescent plasma works best when given early, before the infection has caused extensive damage.
In December 2024, the FDA approved a formal license for high-titer COVID-19 convalescent plasma specifically for treating COVID-19 in patients who are immunosuppressed, either from disease or from medication. Following that approval, the earlier emergency use authorization was revoked in August 2025, since it was no longer needed.
Risks and Side Effects
Convalescent plasma carries the same risks as any blood product transfusion, though serious reactions are uncommon. In a safety study of 20,000 hospitalized COVID-19 patients, the rate of transfusion-associated circulatory overload (where the added fluid strains the heart and lungs) was 0.18%. The rate of transfusion-related acute lung injury (an immune reaction that causes sudden breathing difficulty) was 0.10%. Severe allergic reactions occurred at a similar low rate. These numbers were actually well below the rates typically seen with plasma transfusions in other settings, which historically range from 1% to 8% depending on the complication.
One historical curiosity: in some patients treated for Argentine hemorrhagic fever, a delayed neurological condition appeared several weeks after they had apparently recovered. This was not widely reported with COVID-19 plasma use, but it illustrates that outcomes can vary across different infections.
How It Compares to Monoclonal Antibodies
Monoclonal antibodies are lab-engineered proteins designed to target a specific part of a virus. They are more precise than convalescent plasma, which contains a broad mix of antibodies at varying concentrations. In a direct comparison during the pandemic, all patients treated with monoclonal antibodies survived, while convalescent plasma improved survival to 82% compared to 61% with standard care alone. Severe respiratory disease developed in only 3.8% of the monoclonal antibody group versus 54.5% of the plasma group.
So why use plasma at all? Because monoclonal antibodies take months or years to develop against a new variant, and they don’t always work when the virus mutates. During the Omicron wave, several monoclonal antibody treatments lost effectiveness against new subvariants. Convalescent plasma, by contrast, can be collected from recently recovered patients whose antibodies already match the circulating strain. It is also far more accessible in low-income countries where expensive manufactured biologics may not be available. For immunosuppressed patients facing a new variant with no approved targeted therapy, early administration of well-matched convalescent plasma can make a meaningful difference in survival.
Why Dose and Timing Matter
Two factors consistently determine whether convalescent plasma helps: how many antibodies are in the plasma and how soon the patient receives it. Typical dosing involves one or two units of about 200 mL each, infused at a rate of 100 to 200 mL per hour. When two doses are used, they are spaced at least 12 hours apart. The FDA recommended starting with one high-titer unit and adding more based on the patient’s response.
A Chinese pilot study of 10 critically ill patients found that a single 200 mL dose with a high neutralizing antibody titer cleared detectable virus in seven of them, with both imaging and clinical signs improving. But across multiple studies, the pattern is clear: patients treated within the first few days of diagnosis fare significantly better than those treated later. By the time an infection has triggered widespread inflammation and organ damage, neutralizing the virus alone is no longer enough. Convalescent plasma fights the pathogen, not the downstream damage the pathogen has already caused.